Patent · US Active

Site-specific antibody-drug conjugates

US11702473B2 · kind B2 · utility

0Cited by

87References

10Claims

0Family size

Assignees

MedImmune Limited · US
ADC THERAPEUTICS SA · CH

Inventors

Patricius Hendrikus Cornelis Van Berkel · Épalinges, CH
Philip Wilson Howard · London, GB

Key dates

Filing date	Nov 14, 2019
Grant date	Jul 18, 2023
Priority date	—
Expiry date	Oct 9, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/55
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.